NL
BIIB icon

NorthAvenue LLC’s Biogen BIIB Stock Holding History

NorthAvenue LLC’s Portfolio BIIB Stock Details BIIB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$217 Hold
1
– – ﹤0.01% 300
2026
Q1 		$184 Hold
1
– – ﹤0.01% 256
2025
Q4 		$176 Buy
+1
New +$163 ﹤0.01% 345

Other funds holding BIIB

Robeco Institutional Asset Management
Robeco Institutional Asset Management Rotterdam, Netherlands $81.4B AUM 40.71% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
AAMU
AEGON Asset Management (UK) Edinburgh, United Kingdom $9.38B AUM 48.94% 1-Year Est. Return
ADEF
Adams Diversified Equity Fund Baltimore, Maryland $3.27B AUM 45.57% 1-Year Est. Return
Handelsbanken Fonder
Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return
GIA
Gateway Investment Advisers Cincinnati, Ohio $10.1B AUM 40.26% 1-Year Est. Return
NGM
North Growth Management Vancouver, British Columbia, Canada $780M AUM 102.77% 1-Year Est. Return
QCM
QRG Capital Management Chicago, Illinois $12.1B AUM 44.98% 1-Year Est. Return
CIM
Contravisory Investment Management Norwell, Massachusetts $566M AUM 42.93% 1-Year Est. Return
GIC
Generali Investments CEE Prague, Czech Republic $2.11B AUM 25.53% 1-Year Est. Return

NorthAvenue LLC's BIIB Position: Q2 2026 in Review

NorthAvenue LLC held its Biogen (BIIB) position steady in Q2 2026 at 1 share worth $217. The position accounts for ﹤0.01% of the portfolio, ranked #300.

NorthAvenue LLC first reported a position in BIIB in Q4 2025 and has held it in 3 quarters since. 191 funds tracked by Wall St. Rank hold BIIB as of Q2 2026.

  • NorthAvenue LLC held 1 share of Biogen worth $217 as of Q2 2026.
  • NorthAvenue LLC left its Biogen share count unchanged in Q2 2026.
  • Biogen made up ﹤0.01% of NorthAvenue LLC's portfolio in Q2 2026, its #300 holding.
  • NorthAvenue LLC first reported a position in Biogen in Q4 2025 and has held it in 3 quarters since.
  • 191 funds tracked by Wall St. Rank held Biogen as of Q2 2026.

Based on NorthAvenue LLC's 13F filing for Q2 2026, filed 21 Jul 2026.